Protagonist Therapeutics (PTGX) Earnings Analysis
Protagonist Therapeutics (PTGX) has no confirmed upcoming earnings date. Last quarter (2025-11-06) it missed with EPS -0.62 USD vs -0.59 USD est (-5.1%). It has beaten estimates in 1/2 recent quarters (50%). Trailing P/E -75.17.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does PTGX next report earnings?
No confirmed upcoming earnings date is currently scheduled for PTGX. This page updates as the calendar is published.
PTGX earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2025-11-06 | -0.62 USD | -0.59 USD | -5.1% | Miss |
| 2025-02-21 | 1.98 USD | 0.06 USD | +3200% | Beat |
Beat rate: 1/2 (50%) over reported quarters with consensus data.
PTGX valuation and analyst view
| Trailing P/E | -75.17 |
|---|---|
| Trailing EPS | -1.7624 USD |
| Price / book | 13.45 |
| Dividend yield | 0.00% |
| Market cap | 8.68B |
| Analyst consensus | Buy (25 buy / 1 hold / 0 sell) |
| Avg price target | 142.75 USD |
Related research pages
Frequently asked questions
When is Protagonist Therapeutics (PTGX)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for PTGX. This page updates as the calendar is published.
Did PTGX beat earnings last quarter?
In its 2025-11-06 report, PTGX posted EPS of -0.62 USD versus a -0.59 USD estimate — a miss of 5.1%.
What is PTGX's earnings track record?
Over the last 2 reported quarters with consensus data, PTGX beat estimates 1 times (50%).
What is PTGX's current P/E ratio and EPS?
PTGX trades at a trailing P/E of -75.17 on trailing EPS of -1.7624027416362382 USD.
What do analysts rate PTGX?
Analyst consensus is "Buy" across 26 ratings (0 strong buy, 25 buy, 1 hold, 0 sell, 0 strong sell). Average 12-month price target: 142.75 USD.